WO2006028120A1 - 肥満予防・改善剤 - Google Patents
肥満予防・改善剤 Download PDFInfo
- Publication number
- WO2006028120A1 WO2006028120A1 PCT/JP2005/016400 JP2005016400W WO2006028120A1 WO 2006028120 A1 WO2006028120 A1 WO 2006028120A1 JP 2005016400 W JP2005016400 W JP 2005016400W WO 2006028120 A1 WO2006028120 A1 WO 2006028120A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- corn starch
- starch
- agent
- improving
- obesity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Definitions
- the present invention relates to a preventive / ameliorating agent for obesity, diabetes and the like.
- a method generally proposed by a dietitian includes intake of a low calorie diet or a low fat diet.
- water-insoluble dietary fibers such as wheat bran
- water-soluble dietary fibers such as indigestible dextrin
- digestion-resistant starches such as high amylose starch
- Non-Patent Document 1 water-insoluble dietary fibers
- sugar absorption It has an inhibitory action (for example, see Non-Patent Document 2), a blood neutral fat lowering action (for example, see Non-Patent Document 3), or a glucose tolerance improving action
- Non-Patent Document 4 Non-Patent Document 4, (See Patent Literature 5 and Non-Patent Literature 6), which is considered to be effective in preventing and improving obesity and preventing diabetes.
- the low-calorie diet or the low-fat diet may have some temporary effects on weight loss, but it is long because the flavor of the food that makes it up is monotonous. Over time, it will be rejected by the person and it is difficult to maintain it for a long time.
- food materials such as the above-mentioned conventional water-insoluble dietary fiber, water-soluble dietary fiber, and digestion-resistant starch must continue to be ingested at a high dose for a long period of time in order to exhibit the above physiological effects. Yes. In addition, even if the physiological action is expressed, suppression of obesity has not been confirmed.
- Starch corn starch which is a starch derived from glutinous corn (xylon corn), is composed of 100% amylobectin, has high swelling power, low gelatinization temperature, low aging property, and high transparency. It is widely used in foods such as rice crackers, packaging rice cakes, cold plum powder, white egg flour, sauces, and salad dressings. It is also widely used in the production and processing of noodles, frozen foods, confectionery and pasty foods for the purpose of improving texture, freezing resistance, transparency of paste liquid, and stringiness (for example, (See Patent Document 7).
- starch corn starch has the effect of preventing and improving the development of lifestyle-related diseases such as obesity and diabetes.
- Patent Document 1 Japanese Patent Laid-Open No. 5-186356
- Patent document 2 JP-A-3-290170
- Non-Patent Document 2 Journal of the Japan Endocrine Society 1992 68 (6): 623-35
- Non-Patent Document 3 Am J Clin Nutr 1989 49 (2): 337- 44
- Non-Patent Document 4 Acta Paediatr Hung 1985 26 (1): 75-7
- Non-Patent Document 5 J Endocrinol 1995 144 (3): 533-8
- Non-Patent Document 6 Am J Clin Nutr 1989 49 (2): 337—44
- Non-Patent Document 7 Eiji Fuwa, Toshiaki Komine, Susumu Tatsumi, written by Kakinuma Shinji, “Encyclopedia of Starch Science”, Asakura Shoten, 2003, p.503-518
- the present invention relates to an obesity prevention / amelioration agent, a visceral fat accumulation inhibitor, a blood sugar level increase inhibitor, a blood insulin increase inhibitor, a diabetes prevention / amelioration agent, lipid metabolism, which contains oxy-corn starch as an active ingredient.
- the present invention relates to an improver and a fatty acid oxidizer.
- the present invention provides an obesity prevention / amelioration agent, a visceral fat accumulation inhibitor, a blood sugar level increase inhibitor,
- the present invention relates to the use of xylone corn starch to produce a blood insulin elevation inhibitor, diabetes prevention / amelioration agent, lipid metabolism improvement agent and fatty acid oxidation promoter.
- the present invention provides a method for improving obesity prevention, a method for suppressing visceral fat accumulation, a method for suppressing an increase in blood sugar level, a method for suppressing an increase in blood insulin, characterized by administering or ingesting oxy corn starch.
- the present invention relates to a method for inhibiting, a method for improving diabetes prevention, a method for improving lipid metabolism, and a method for promoting fatty acid oxidation.
- the present invention provides a food for improving obesity containing oxy-corn starch, a food for improving visceral fat accumulation, a food for suppressing blood sugar level increase, a food for suppressing blood insulin rise, a diabetes preventive
- the present invention relates to a food for improvement, a food for improving lipid metabolism, and a food for promoting fatty acid oxidation.
- the present invention exhibits the effect of preventing and improving various lifestyle-related diseases such as obesity prevention 'improvement agent, prevention of hyperlipidemia', etc., and has high safety and wide application range. It relates to providing materials such as pharmaceuticals.
- the present inventors have a material having physical properties different from those of conventional dietary fibers represented by indigestible starch, cellulose, and indigestible dextrin, and has an action of suppressing or improving the progression of obesity and diabetes.
- the corn starch has a variety of physiological effects, including obesity-inhibiting effects, even with a small amount of intake, and is a pharmaceutical material that exhibits the effect of preventing and improving lifestyle-related diseases such as obesity and diabetes As found useful.
- Axylone corn starch is composed of 100% amylopectin in which glucose is polymerized in a branched chain. Amylopectin is thought to be more easily consumed than amylose in which glucose is polymerized in a straight chain, and as a result, postprandial blood glucose and blood insulin levels are likely to increase (GH Anderson, supervised by Shuichi Kimura, supervised by Adachi Tsuji) , “Glycemic Carbonate and Health J Kenpakusha 2003 p. 45). Therefore, such xyxy corn starch can be used to improve various obesity 'preventing diabetes' as described above. The effect is quite surprising.
- the obesity prevention 'improving agent or the like of the present invention is used for the prevention of obesity' improvement, prevention of hyperlipidemia, prevention of heart diseases such as heart failure, prevention of thrombosis, prevention of colon cancer and rectal cancer. Preventing the development of various lifestyle-related common diseases, etc. And useful.
- xy-corn starch which is an active ingredient, is excellent in safety to the human body and easily gelatinized. Therefore, when blended with foods for specified health use, it is less likely to impair the original texture.
- the waxy corn starch of the present invention is a starch derived from a glutinous corn (boiled corn).
- glutinous corn boiled corn
- those used as thickeners and the like can be used.
- pregelatinized starch corn starch obtained by pregelatinizing the above waxy corn starch by heating in water or the like can also be used.
- oxyxy corn starch has an obesity-suppressing action in which the body weight and visceral fat amount are significantly reduced, and thus hyperlipidemia caused by obesity. It can exert effects such as prevention of heart disease, prevention of heart diseases such as heart failure, prevention of thrombosis, prevention of hypertension and the like.
- postprandial hyperglycemia or hyperinsulinemia that is, it has the effect of suppressing rapid increases in postprandial blood glucose level and blood insulin level, as well as the suppression of steady-state blood glucose level and blood insulin level. It can exert effects such as prevention of diabetes and various complications resulting therefrom, such as cataract, periodontal disease, diabetic nephropathy, retinopathy, and neuropathy.
- it has the effect of enhancing the expression level of lipid metabolism-related proteins in the liver and promoting fatty acid oxidation activity, and thus can exert effects such as prevention of hyperlipidemia and fatty liver.
- the xyxy corn starch of the present invention is an obesity preventive / ameliorating agent, visceral fat accumulation inhibitor, blood sugar level increase inhibitor, blood insulin increase inhibitor, diabetes prevention / amelioration agent, lipid metabolism improving agent, fatty acid oxidation.
- an accelerator hereinafter referred to as obesity prevention, amelioration agent, etc.
- it can be a material for drugs or functional foods mainly for humans or animals.
- the obesity prevention / amelioration agent of the present invention can be administered to humans and animals alone or in combination with one or more starch corn starches, and can be ingested in pharmaceuticals, functional foods and drinks, pet foods, etc. be able to.
- Functional foods can be applied to beauty foods, sick foods, foods for special health use, etc., with the concept of physiological functions such as body fat accumulation suppression and blood sugar level increase suppression as necessary.
- oral solid preparations such as tablets and granules
- oral liquid preparations such as oral liquids and syrups may be used. it can.
- an excipient When preparing an oral solid preparation, an excipient, if necessary, a binder, a disintegrant, a lubricant, a coloring agent, a corrigent, a corrigent and the like are added to the starch corn starch of the present invention. Thereafter, tablets, coated tablets, granules, powders, capsules and the like can be produced by conventional methods.
- a liquid preparation, a syrup, an elixir, etc. can be manufactured by a conventional method by adding a corrigent, a buffer, a stabilizer, a corrigent and the like.
- the amount of waxy corn starch to be blended in each of the above preparations is usually 5 to: LOO weight%, preferably 20 to: LOO weight%, more preferably 30 to LOO weight%. Is preferred.
- the dose (effective intake) of the agent for preventing obesity according to the present invention is preferably not less than 0. OlgZkg body weight per day, particularly not less than 0. lgZkg body weight, more preferably not less than 0.4 gZkg body weight. It is preferable that
- Test Example 1 Obesity-inhibiting action, blood glucose level-inhibiting action
- Tapio starch and starch corn starch were obtained from National Starch and Chemical Company. The above starch was suspended in distilled water to 50% by weight, autoclaved (wet heat treatment) at 120 ° C for 15 minutes, and then freeze-dried to prepare a test starch that was pregelatinized. In addition, a-modified potato starch was obtained commercially from Oriental Yeast Co., Ltd.
- mice There were 10 mice (C57BLZ6J male, 6 weeks old) per group, and they were bred using various pregelatinized starches and diets prepared with the formulations shown in Table 1. After 24 weeks of breeding, the mice were bled and sacrificed, and blood glucose levels, blood insulin levels, and visceral fat weights were measured. Table 2 shows the body weight, visceral fat weight, blood glucose level and blood insulin level after 24 weeks of breeding.
- mice fed a high-fat diet containing 5% tapio starch increased obesity with higher body weight and visceral fat weight than mice fed a low-fat diet.
- mice fed a high-fat diet containing 5% tapio starch increased obesity with higher body weight and visceral fat weight than mice fed a low-fat diet.
- mice fed a high fat diet containing 5% tapio starch had significantly higher blood sugar levels and blood insulin levels during non-fasting compared to mice fed a low fat diet. It was. Increased blood glucose level in mice that received a high-fat diet containing 5% starch corn starch and lower blood glucose and blood insulin levels compared to mice fed a diet containing tapio starch It can be seen that an inhibitory effect and an improvement effect on hyperinsulinemia are observed.
- Test Example 2 Enhancement of lipid metabolism
- mice C57BLZ6J male, 6 weeks old
- mice were bred using food prepared with the formulation shown in Table 3.
- Table 4 shows the expression level of genes (mRNA) of lipid metabolism-related proteins in the liver measured by quantitative RT-PCR.
- mice fed a diet containing 10% starch corn starch lipid metabolism-related proteins (MCAD) in the liver were compared to mice fed a diet formulated with tapio starch.
- L—FABP, FAT lipid metabolism-related proteins
- Test Example 3 Enhancement of lipid metabolism
- 20 mice C57BLZ6J male, 6 weeks old
- Table 3 shows the fatty acid acid activity of the liver measured according to the previously reported method (Murase. T. et al. Int J Obes Relat Metab Disord. 2002 Nov; 26 (11): 1459-64.).
- liver fatty acid acid activity is significantly higher in mice fed with 10% corn starch starch compared to mice fed tapio starch. It is obvious that lipid metabolism is increased.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2578952A CA2578952C (en) | 2004-09-09 | 2005-09-07 | Waxy corn starch and use thereof for treating obesity and diabetes |
US11/662,227 US20080096842A1 (en) | 2004-09-09 | 2005-09-07 | Preventive/Remedy for Obesity |
AU2005280992A AU2005280992B2 (en) | 2004-09-09 | 2005-09-07 | Preventive/remedy for obesity |
EP05782232A EP1787625B1 (en) | 2004-09-09 | 2005-09-07 | Preventive/remedy for obesity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-262493 | 2004-09-09 | ||
JP2004262493A JP4791721B2 (ja) | 2004-09-09 | 2004-09-09 | 肥満予防・改善剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006028120A1 true WO2006028120A1 (ja) | 2006-03-16 |
Family
ID=36036401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/016400 WO2006028120A1 (ja) | 2004-09-09 | 2005-09-07 | 肥満予防・改善剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080096842A1 (ja) |
EP (1) | EP1787625B1 (ja) |
JP (1) | JP4791721B2 (ja) |
AU (1) | AU2005280992B2 (ja) |
CA (1) | CA2578952C (ja) |
WO (1) | WO2006028120A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4915717B2 (ja) * | 2004-09-09 | 2012-04-11 | 花王株式会社 | 肥満予防・改善剤 |
JP4878494B2 (ja) * | 2006-04-24 | 2012-02-15 | 花王株式会社 | 食後血中インスリン上昇抑制剤 |
MX2009003389A (es) * | 2006-10-03 | 2009-04-09 | Wyeth Corp | Metodos y aparatos de liofilizacion. |
JP2009207366A (ja) * | 2008-02-29 | 2009-09-17 | Kao Corp | ペットフード |
JP5768252B2 (ja) * | 2009-08-12 | 2015-08-26 | 公立大学法人大阪府立大学 | 抗脂血及び内臓脂肪予防食品 |
JP6300597B2 (ja) * | 2014-03-28 | 2018-03-28 | サンスター株式会社 | 米糠配合膨化食品 |
CN104814374B (zh) * | 2015-05-20 | 2018-08-14 | 山东省农业科学院农产品研究所 | 一种糖尿病肾病专用即食冲调粉及其制备方法 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5939260A (ja) * | 1982-08-31 | 1984-03-03 | Nippon Shokuhin Kako Kk | 飲食品の製造法 |
DE3519645A1 (de) | 1985-06-01 | 1986-12-04 | Michael Dr. 7056 Weinstadt Osswald | Diaetnahrungsmittel |
JPH04281764A (ja) * | 1991-03-30 | 1992-10-07 | Nippon Shokuhin Kako Co Ltd | 飲食品の製造法 |
JPH0649101A (ja) * | 1992-06-16 | 1994-02-22 | Soc Prod Nestle Sa | ワキシー澱粉生成物の製造法 |
JPH06225719A (ja) * | 1993-02-02 | 1994-08-16 | Otsuka Shokuhin Kk | 低カロリー食品素材およびその製造方法 |
EP0648425A2 (en) | 1993-10-18 | 1995-04-19 | Kraft Foods, Inc. | Fat-free or low fat tablespread |
JPH07184531A (ja) * | 1993-12-27 | 1995-07-25 | Asahi Breweries Ltd | ウエハース |
JPH10279487A (ja) | 1997-04-01 | 1998-10-20 | Nippon Shokuhin Kako Co Ltd | 脂質代謝改善剤 |
JPH11286497A (ja) * | 1998-03-31 | 1999-10-19 | Hayashibara Biochem Lab Inc | グリコシル−l−アスコルビン酸のアシル化誘導体 |
US6099871A (en) | 1995-06-01 | 2000-08-08 | Bristol-Myers Squibb Company | Anti-regurgitation infant formula |
US6221420B1 (en) | 1993-07-30 | 2001-04-24 | National Starch And Chemical Investment Holding Corporation | Foods containing thermally-inhibited starches and flours |
FR2809928A1 (fr) | 2000-05-09 | 2001-12-14 | Nagatien Co Ltd | Premelage pour gateau du type genoise, pate preparee avec ce premelange, et procede de fabrication de genoise en utilisant le premelange |
JP2002538846A (ja) | 1999-03-24 | 2002-11-19 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | シリアルバー |
JP2003310187A (ja) * | 2002-04-26 | 2003-11-05 | Otsuka Shokuhin Kk | 低カロリー食品素材 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4510166A (en) * | 1984-01-19 | 1985-04-09 | National Starch And Chemical Corporation | Converted starches for use as a fat- or oil-replacement in foodstuffs |
GB9106569D0 (en) * | 1991-03-27 | 1991-05-15 | Cerestar Holding Bv | Starch esters |
US5387423A (en) * | 1992-07-24 | 1995-02-07 | Otsuka Foods Co., Ltd. | Low calorie food material and method of manufacturing the same |
ATE556601T1 (de) * | 1999-01-29 | 2012-05-15 | Cooperatie Avebe U A | Zusammensetzung auf basis von vernetzer stärke und depolymerisierter stärke als gelatin-ersatz |
DE60016726T2 (de) * | 1999-03-24 | 2006-04-27 | Société des Produits Nestlé S.A. | Verfahren zur herstellung eines expandierten snackprodukts mit hohem milchfeststoffanteil |
WO2002071869A1 (en) * | 2001-03-13 | 2002-09-19 | Massachusetts Institute Of Technology | Weight loss compositions and methods for individuals who may have gastric hyperacidity |
FR2840612B1 (fr) * | 2002-06-06 | 2005-05-06 | Roquette Freres | Polymeres solubles de glucose hautement branches et leur procede d'obtention |
JP5026657B2 (ja) * | 2003-03-11 | 2012-09-12 | 花王株式会社 | 肥満予防・改善剤 |
JP4915717B2 (ja) * | 2004-09-09 | 2012-04-11 | 花王株式会社 | 肥満予防・改善剤 |
DE102005003299A1 (de) * | 2005-01-24 | 2006-07-27 | Goldschmidt Gmbh | Nanopartikel für die Herstellung von Polyurethanschaum |
-
2004
- 2004-09-09 JP JP2004262493A patent/JP4791721B2/ja not_active Expired - Fee Related
-
2005
- 2005-09-07 EP EP05782232A patent/EP1787625B1/en not_active Revoked
- 2005-09-07 CA CA2578952A patent/CA2578952C/en not_active Expired - Fee Related
- 2005-09-07 WO PCT/JP2005/016400 patent/WO2006028120A1/ja active Application Filing
- 2005-09-07 US US11/662,227 patent/US20080096842A1/en not_active Abandoned
- 2005-09-07 AU AU2005280992A patent/AU2005280992B2/en not_active Ceased
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5939260A (ja) * | 1982-08-31 | 1984-03-03 | Nippon Shokuhin Kako Kk | 飲食品の製造法 |
DE3519645A1 (de) | 1985-06-01 | 1986-12-04 | Michael Dr. 7056 Weinstadt Osswald | Diaetnahrungsmittel |
JPH04281764A (ja) * | 1991-03-30 | 1992-10-07 | Nippon Shokuhin Kako Co Ltd | 飲食品の製造法 |
JPH0649101A (ja) * | 1992-06-16 | 1994-02-22 | Soc Prod Nestle Sa | ワキシー澱粉生成物の製造法 |
JPH06225719A (ja) * | 1993-02-02 | 1994-08-16 | Otsuka Shokuhin Kk | 低カロリー食品素材およびその製造方法 |
US6221420B1 (en) | 1993-07-30 | 2001-04-24 | National Starch And Chemical Investment Holding Corporation | Foods containing thermally-inhibited starches and flours |
EP0648425A2 (en) | 1993-10-18 | 1995-04-19 | Kraft Foods, Inc. | Fat-free or low fat tablespread |
JPH07184531A (ja) * | 1993-12-27 | 1995-07-25 | Asahi Breweries Ltd | ウエハース |
US6099871A (en) | 1995-06-01 | 2000-08-08 | Bristol-Myers Squibb Company | Anti-regurgitation infant formula |
JPH10279487A (ja) | 1997-04-01 | 1998-10-20 | Nippon Shokuhin Kako Co Ltd | 脂質代謝改善剤 |
JPH11286497A (ja) * | 1998-03-31 | 1999-10-19 | Hayashibara Biochem Lab Inc | グリコシル−l−アスコルビン酸のアシル化誘導体 |
JP2002538846A (ja) | 1999-03-24 | 2002-11-19 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | シリアルバー |
FR2809928A1 (fr) | 2000-05-09 | 2001-12-14 | Nagatien Co Ltd | Premelage pour gateau du type genoise, pate preparee avec ce premelange, et procede de fabrication de genoise en utilisant le premelange |
JP2003310187A (ja) * | 2002-04-26 | 2003-11-05 | Otsuka Shokuhin Kk | 低カロリー食品素材 |
Non-Patent Citations (8)
Title |
---|
ACTA PAEDIATR HUNG, vol. 26, no. 1, 1985, pages 75 - 7 |
AMJCLIN NUTR, vol. 49, no. 2, 1989, pages 337 - 44 |
EIJI FUWA, TOSHIAKI KOMAKI, SUSUMU HIZUKURI, KEIJI KAINUMA: "Denpun Kagaku No Jiten", 2003, ASAKURA PUBLISHING, pages: 503 - 518 |
ENDOCRINE JOURNAL, vol. 68, no. 6, 1992, pages 623 - 35 |
G. H. ANDERSON: "Glycemic Carbohydrate and Health", 2003, KENPAKUSHA, pages: 45 |
JENDOCRINOL, vol. 144, no. 3, 1995, pages 533 - 8 |
PHYSIOLOGY AND BEHAVIOR, vol. 42, 1997, pages 409 - 415 |
See also references of EP1787625A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP2006076919A (ja) | 2006-03-23 |
EP1787625A4 (en) | 2010-03-17 |
AU2005280992A1 (en) | 2006-03-16 |
JP4791721B2 (ja) | 2011-10-12 |
EP1787625B1 (en) | 2012-12-26 |
AU2005280992B2 (en) | 2011-11-17 |
US20080096842A1 (en) | 2008-04-24 |
CA2578952A1 (en) | 2006-03-16 |
EP1787625A1 (en) | 2007-05-23 |
CA2578952C (en) | 2015-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shah et al. | Health benefits of konjac glucomannan with special focus on diabetes | |
EP2323669B2 (en) | Arabinoxylan for modulating the barrier function of the intestinal surface | |
JP5026657B2 (ja) | 肥満予防・改善剤 | |
WO2006028120A1 (ja) | 肥満予防・改善剤 | |
JP2010534687A5 (ja) | ||
KR101021431B1 (ko) | 소화 지연성 탄수화물로서의 풀룰란의 용도 | |
Wen et al. | Resistant starches and gut microbiota | |
WO2006028122A1 (ja) | 肥満予防・改善剤 | |
Johnson | Dietary fiber | |
Akhtar et al. | Neutraceutical Properties of Resistant Starch | |
EP3761995A1 (en) | Yeast beta glucans | |
Hasbay | Dietary Fiber and Nutrition | |
JP2010053138A (ja) | 肥満予防・改善剤 | |
Aluko et al. | Bioactive carbohydrates | |
JP5118316B2 (ja) | 肥満予防・改善剤 | |
Bansal et al. | Health benefits and importance of Avena sativa L | |
CN115038340A (zh) | 用于改变血糖反应的制剂、组合物或食品添加剂的制造方法及使用 | |
Vinoy et al. | 13 Creating Food Products | |
Lyon | Dietary Fiber | |
JPH10290681A (ja) | 抗肥満作用を有する飲食品 | |
Diabetes | REVIEW OF LITERATURE | |
JP2008220231A (ja) | マルトトリイトールを有効成分とする血糖値上昇抑制剤及び血糖値上昇抑制食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2578952 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11662227 Country of ref document: US Ref document number: 2005782232 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005280992 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005280992 Country of ref document: AU Date of ref document: 20050907 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005280992 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005782232 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11662227 Country of ref document: US |